Syra Health receives Nasdaq delisting notice for equity shortfall; provides 2024 revenue guidance of $7.5-9.5M

Syra Health Corp

Nasdaq notified Syra Health of non-compliance with stockholders' equity minimum of $2.5M (Listing Rule 5550(b)(1)).
Company has 45 days to submit a compliance plan; Nasdaq may grant up to 180-day extension.
Full-year 2024 revenue forecast $7.5-9.5M (36%-73% YoY growth), with majority in H2 due to delayed implementation.
If compliance plan not accepted, stock could be delisted; company can appeal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.